Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial

Publication | Open Access

DOI Full Paper Access

167

Citations

References

2021

Year

Philippe Moreau, Cyrille Hulin, Aurore Perrot, Bertrand Arnulf, Karim Belhadj, Lotfi Benboubker, Marie C. Béné, Sonja Zweegman, Hélène Caillon, Denis Caillot,

The Lancet Oncology

Hematological MalignancyMedicineAutologous Stem-cell TransplantImmunologyHematologyMultiple MyelomaImmunotherapyOncologyMyeloid Neoplasia